Leerink Partnrs Boosts Earnings Estimates for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for Exact Sciences in a research report issued on Thursday, February 20th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $0.12 for the quarter, up from their prior forecast of $0.09. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.27 EPS, Q2 2026 earnings at $0.22 EPS, FY2026 earnings at $0.93 EPS and FY2027 earnings at $1.54 EPS.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 37.29%.

Several other equities research analysts have also issued reports on the company. Piper Sandler dropped their price target on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Craig Hallum lowered their target price on Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. TD Cowen boosted their price target on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein boosted their price target on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $72.06.

Exact Sciences Trading Down 1.9 %

NASDAQ:EXAS opened at $49.51 on Friday. Exact Sciences has a 52-week low of $40.62 and a 52-week high of $79.62. The stock has a fifty day moving average of $55.15 and a 200 day moving average of $60.03. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EXAS. Price T Rowe Associates Inc. MD grew its position in shares of Exact Sciences by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock valued at $323,669,000 after purchasing an additional 2,462,165 shares in the last quarter. Capital World Investors grew its position in shares of Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock valued at $985,439,000 after purchasing an additional 1,696,321 shares in the last quarter. Mackenzie Financial Corp grew its position in Exact Sciences by 107.7% in the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock worth $164,037,000 after acquiring an additional 1,513,873 shares in the last quarter. Groupama Asset Managment purchased a new position in Exact Sciences in the third quarter worth about $821,000. Finally, Norges Bank purchased a new position in Exact Sciences in the fourth quarter worth about $50,625,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.